Age1 is a venture capital firm that primarily invests in biotechnology companies. The firm is driven by a vision to make aging and age-related diseases optional for all.
Aperture Therapeutics is a biotechnology company focused on the development of novel therapies for age-related neurodegenerative diseases. Utilizing a unique drug discovery platform, the company aims to harness the genetic diversity of patients to identify new disease pathways and drug targets. With operations based in a lab incubator, Aperture Therapeutics is in the pre-clinical stage, actively applying insights from neuroscience and immunology to advance its research. The company's approach emphasizes the importance of genetic diversity in the discovery process, aiming to lead to more effective treatments for neurodegeneration and neuroimmunology conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.